Role of vitamin D in autoimmune rheumatic diseases- hype or real?
DOI:
https://doi.org/10.15305/ijrci/v5i1/232Keywords:
Vitamin D, immunomudulator, autoimmuneAbstract
Since the beginning of the 20th century, it has been well known that vitamin D is associated with bone and calcium metabolism. There is increasing evidence on the positive effects of vitamin D on innate and acquired immunities. Many studies have reported the relation between polymorphisms of the vitamin D receptor (VDR) and the onset of various autoimmune rheumatic diseases (AIRD). Studies conducted in animal models have reported vitamin D supplementation as an effective therapy for various autoimmune diseases. Whereas, prospective human studies have reported contradictory findings on the effect of vitamin D levels or intake on autoimmune risk. In the present review, the authors have attempted to summarize the association between vitamin D and AIRD.
References
Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(1):34-45. doi:10.1136/ard.2005.044354.
Mednet - CME, CHE | Rapid Treatment Response in Rheumatoid Arthritis: A Valuable Indicator of Reduced Risk of Joint Damage. http://www.mednet.ca/en/report/rapid-treatment-response-in-rheumatoid-arthritis.html. Accessed October 31, 2015.
Rantalaiho V, Kautiainen H, Järvenpää S, et al. Failure in long term treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial. J Rheumatol. 2014;41(12):2379-2385. doi:10.3899/jrheum.140267.
Kuriya B, Xiong J, Boire G, et al. Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis--results from the Canadian Early Arthritis Cohort (CATCH). J Rheumatol. 2014;41(11):2161-2166. doi:10.3899/jrheum.140137.
Ma MHY, Ibrahim F, Walker D, et al. Remission in early rheumatoid arthritis: predicting treatment response. J Rheumatol. 2012;39(3):470-475. doi:10.3899/jrheum.110169.
Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. Rheumatology (Oxford). 2007;46(6):975-979. doi:10.1093/rheumatology/kem007.
Gramling A, O’Dell JR. Initial management of rheumatoid arthritis. Rheum Dis Clin North Am. 2012;38(2):311-325. doi:10.1016/j.rdc.2012.05.003.
Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381-3390. doi:10.1002/art.21405.
Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263-269. doi:10.1016/S0140-6736(04)16676-2.
Schipper LG, Fransen J, den Broeder AA, Van Riel PLCM. Time to achieve remission determines time to be in remission. Arthritis Res Ther. 2010;12(3):R97. doi:10.1186/ar3027.
Verstappen SMM, van Albada-Kuipers GA, Bijlsma JWJ, et al. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis. 2005;64(1):38-43. doi:10.1136/ard.2003.014928.
Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis. 1995;54(12):944-947.
Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964-975. doi:10.1136/ard.2009.126532.
Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-639. doi:10.1002/acr.21641.
Madsen OR. Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice? Clin Rheumatol. 2011;30(12):1577-1582. doi:10.1007/s10067-011-1847-6.
Steyerberg EW, Harrell FE, Borsboom GJJM, Eijkemans MJC, Vergouwe Y, Habbema JDF. Internal validation of predictive models. Journal of Clinical Epidemiology. 2001;54(8):774-781. doi:10.1016/S0895-4356(01)00341-9.
S Chandrashekara. Quantification of inflammation: Needs and challenges. Internet Journal of Rheumatology and Clinical Immunology. 2014;2(S1). doi:10.15305/ijrci/v2iS1/91.
Venkatraghavan L, Tan TP, Mehta J, Arekapudi A, Govindarajulu A, Siu E. Neutrophil Lymphocyte Ratio as a predictor of systemic inflammation - A cross-sectional study in a pre-admission setting. F1000Research. May 2015. doi:10.12688/f1000research.6474.1.
Fu H, Qin B, Hu Z, et al. Neutrophil- and platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis. Clin Lab. 2015;61(3-4):269-273.
Gangat N, Wolanskyj AP. Anemia of Chronic Disease. Seminars in Hematology. 2013;50(3):232-238. doi:10.1053/j.seminhematol.2013.06.006.
N G, U T, Ag J, et al. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: long term course and association to radiographic progression. J Rheumatol. 2000;27(1):47-57.
Thorne C, Bensen WG, Choquette D, et al. Effectiveness and Safety of Infliximab in Rheumatoid Arthritis: Analysis From a Canadian Multicenter Prospective Observational Registry. Arthritis Care & Research. 2014;66(8):1142-1151. doi:10.1002/acr.22290.
Hetland ML. Modern treatment strategies in rheumatoid arthritis. Dan Med Bull. 2011;58(11):B4320.
Ten Klooster PM, Vonkeman HE, Oude Voshaar MAH, Siemons L, van Riel PLCM, van de Laar MAFJ. Predictors of satisfactory improvements in pain for patients with early rheumatoid arthritis in a treat-to-target study. Rheumatology (Oxford). 2015;54(6):1080-1086. doi:10.1093/rheumatology/keu449.
Cannon GW, Wang BC, Park GS, Koenig A, Collier DH, Keystone EC. Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience. Clin Exp Rheumatol. 2013;31(6):919-925.
Jawaheer D, Messing S, Reed G, et al. Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2012;64(12):1811-1818. doi:10.1002/acr.21762.
Chandrashekara S, Priyanka BU. Remission in rheumatoid arthritis by different criteria does not converge over the inflammatory markers. Int J Rheum Dis. 2013;16(3):291-296. doi:10.1111/1756-185X.12091.
Contreras-Yáñez I, Rull-Gabayet M, Pascual-Ramos V. Early disease activity suppression and younger age predict excellent outcome of recent-onset rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs. Clin Exp Rheumatol. 2012;30(3):402-408.
Salgado E, Maneiro JR, Carmona L, Gómez-Reino J. Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: systematic review and meta-analysis of observational studies. Joint Bone Spine. 2014;81(1):41-50. doi:10.1016/j.jbspin.2013.04.004.
Sakthiswary R, Shaharir SS, Mohd Said MS, Asrul AW, Shahril NS. IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor α inhibitors in rheumatoid arthritis. Int J Rheum Dis. 2014;17(8):872-877. doi:10.1111/1756-185X.12443.
Gossec L, Dougados M, Goupille P, et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis. 2004;63(6):675-680. doi:10.1136/ard.2003.010611.
Pincus T, Sokka T, Kavanaugh A. Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for “near remission” of DAS or single measures. Clin Exp Rheumatol. 2004;22(5 Suppl 35):S50-S56.
Rezaei H, Saevarsdottir S, Forslind K, et al. In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis. 2012;71(2):186-191. doi:10.1136/annrheumdis-2011-200038.
Villaverde García V, Balsa Criado A. Does early treatment of Rheumatoid Arthritis lead to a better long-term prognosis? Reumatología Clínica (English Edition). 2010;6(2):106-110. doi:10.1016/S2173-5743(10)70024-1.
Fautrel B, Granger B, Combe B, Saraux A, Guillemin F, Le Loet X. Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort. Arthritis Res Ther. 2012;14(6):R249. doi:10.1186/ar4092.
Forslind K, Hafström I, Ahlmén M. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis. 2007;66(1):46-52. doi:10.1136/ard.2006.056937.
Demoruelle MK, Deane KD. Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis. Curr Rheumatol Rep. 2012;14(5):472-480. doi:10.1007/s11926-012-0275-1.
Kyburz D, Gabay C, Michel BA, Finckh A, physicians of SCQM-RA.
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Rheumatology (Oxford). 2011;50(6):1106-1110. doi:10.1093/rheumatology/keq424.
Additional Files
Published
Issue
Section
License
Copyright for articles published in this journal is retained by the authors, with first publication rights granted to the ‘Internet Journal of Rheumatology and Clinical Immunology’. All the published content, except where otherwise noted, is licensed under Creative Commons license (CC-BY).
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication of the manuscript in IJRCI, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
